Calliditas files sNDA to US FDA for TARPEYO to treat primary IgAN

22 Jun 2023
www.pharmaceutical-technology.com
Phase 3Drug ApprovalClinical ResultAccelerated Approval
Calliditas files sNDA to US FDA for TARPEYO to treat primary IgAN
Preview
Source: Pharmaceutical Technology
The TARPEYO delayed-release capsules are indicated for reducing proteinuria to treat primary immunoglobulin A nephropathy in adult patients. Credit: Alexander Grey on Unsplash.
Calliditas Therapeutics has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for complete approval of TARPEYO (budesonide).
The TARPEYO delayed-release capsule is a corticosteroid indicated for reducing proteinuria to treat primary immunoglobulin A nephropathy (IgAN) in adult patients at risk of quick disease progression, generally having a urine protein-to-creatinine ratio greater than or equal to 1.5g/g.
Recommended Reports
Calliditas files sNDA to US FDA for TARPEYO to treat primary IgAN
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Aspirin + Dimethyl Fumarate) in Relapsing Remitting Multiple Sclerosis (RRMS) GlobalData
Calliditas files sNDA to US FDA for TARPEYO to treat primary IgAN
Preview
Source: Pharmaceutical Technology
ReportsProlyl Endopeptidase (Post Proline Cleaving Enzyme or PREP or EC 3.4.21.26) Drugs in Development ... GlobalData
View allCompanies IntelligenceCalliditas Therapeutics ABSNDANefecon ABView all
The therapy received accelerated approval based on showing a reduction in proteinuria.
The submission of sNDA to the regulator was based on the findings obtained from the Phase III NefIgArd clinical trial.
The multicentre, randomised, double-blind trial was designed to evaluate the safety and efficacy of TARPEYO 16 mg compared with placebo against a background of optimised RASi (renin–angiotensin system inhibitor)RASi (renin–angiotensin system inhibitor) therapy in primary IgA adult patients.
TARPEYO showed a highly statistically significant benefit in estimated glomerular filtration rate (eGFR) over a two-year period of treatment. The treatment period comprises nine months on TARPEYO or placebo, then 15 months of follow-up.
Calliditas Therapeutics CEO Renée Aguiar-Lucander stated: “The eGFR treatment benefit observed across the entire study population, irrespective of UPCR levels, provides further evidence that targeting IgAN at its source can offer patients a treatment that holds the promise of being disease-modifying.
“We are pleased to be able to provide the FDA with the full results of our Phase III study, and we look forward to interactions with the FDA regarding full approval of TARPEYO.”
The company is also collaborating with its European commercial partner STADA Arzneimettel to seek complete approval for NefeconNefecon, branded as Kinpeygo, from the European Commission.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.